What’s the ‘Plus’ in QuantiFERON®-TB Gold Plus?

Oct 25, 2017 1:00 PM–2:00 PM (EDT)
Duration: 1hrs
QuantiFERON®-TB Gold Plus is now FDA approved and will soon launch in the US. The new QFT®-Plus features innovative CD8 technology that provides a more comprehensive picture of a patient’s immune response to TB antigens. Join Dr. Masae Kawamura for a dynamic discussion regarding scientific advancements in TB testing and CD8 technology, including a review of case scenarios applying the insight of QFT-Plus. This program is designed specifically to meet the needs of TB Controllers and others working in the Public Health sector.

Masae Kawamura, M.D.

Dr. Kawamura is QIAGEN’s Senior Director of Scientific and Medical Affairs for TB diagnostics. She has been a TB clinician for more than 25 years and served as San Francisco’s TB Controller from 1996 to the end of 2011. Over a decade ago, under Dr. Kawamura's leadership to promote public health innovation and operations research, San Francisco became the first jurisdiction in the United States to implement interferon gamma release assay (IGRA) blood testing for TB as part of routine screening practice and eventually, contact investigation.